AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Ionis Pharmaceuticals Q2 2025 Earnings Call Transcript
ByAinvest
Wednesday, Jul 30, 2025 4:43 pm ET1min read
Ionis Pharmaceuticals reported Q2 2025 earnings, with CEO Brett Monia and CFO Beth Hougen discussing financial results and product developments. The company's net revenue increased to $133.4 million, driven by strong sales of SPINRAZA and TEGSEDI. Ionis also highlighted progress in its clinical pipeline, including positive data from the CARMINE trial for AKCEA-APOCIII-LRx. The company's non-GAAP net income was $32.1 million, or $0.88 per share.
Ionis Pharmaceuticals Inc. (IONS) reported its second-quarter 2025 financial results, with a significant improvement in earnings and revenue. The company's adjusted earnings per share (EPS) came in at $0.85, compared to the expected loss of $0.52, and the revenue reached $452 million, surpassing the consensus estimate of $282.95 million [1].The strong performance was driven by the successful launch of Tryngolza (olezarsen), the first FDA-approved treatment for familial chylomicronemia syndrome, and increased royalty and R&D revenues. Tryngolza generated net product sales of $19 million in the second quarter, contributing to the overall revenue growth [1].
The company also highlighted progress in its clinical pipeline, including positive data from the CARMINE trial for AKCEA-APOCIII-LRx. Additionally, the drug received a positive opinion from the Committee for Medicinal Products for Human Use, paving the way for its approval in Europe [1].
Ionis raised its fiscal 2025 sales guidance to $825 million-$850 million, compared to the previous estimate of $725 million-$750 million. The company expects a 2025 adjusted operating loss of $300 million-$325 million, with cash, cash equivalents, and short-term investments of around $2 billion [1].
The stock price of Ionis Pharmaceuticals has seen a positive reaction to the earnings report, with the stock up 5.23% at $43.65 at publication [1].
References:
[1] https://www.benzinga.com/markets/earnings/25/07/46733874/ionis-posts-surprise-q2-profit-double-revenues-on-stronger-sales-from-newly-approved-genetic-disease-drug
[2] https://www.gurufocus.com/news/3016122/ionis-reports-second-quarter-2025-financial-results-and-highlights-progress-on-key-programs
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet